Peter Rossing

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi request reprint Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus
    P Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabet Med 15:900-19. 1998
  2. ncbi request reprint Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus
    P Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabet Med 18:199-205. 2001
  3. ncbi request reprint Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study
    Peter Rossing
    Steno Diabetes Center, Gentofte, Denmark Novo Nordisk, Biostatistics, Bagsvaerd, Denmark
    Diabetes Care 25:859-64. 2002
  4. ncbi request reprint Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Steen Andersen
    Steno Diabetes Center, Copenhagen, Denmark
    Diabetes Care 26:1501-6. 2003
  5. doi request reprint Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate
    Henrik Reinhard
    Steno Diabetes Centre, Gentofte, Denmark
    Nephrol Dial Transplant 26:3242-9. 2011
  6. pmc 24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study
    Simone Theilade
    Steno Diabetes Center, Niels Steensensvej 1, 2820 Gentofte, Denmark
    Cardiovasc Diabetol 12:122. 2013
  7. pmc NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients
    Henrik Reinhard
    Steno Diabetes Center, Niels Steensenvej 1, DK 2820 Gentofte, Denmark
    Cardiovasc Diabetol 11:19. 2012
  8. ncbi request reprint Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    Scand J Clin Lab Invest 68:731-8. 2008
  9. doi request reprint Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease
    Stine E Nielsen
    Steno Diabetes Center, Gentofte, Denmark
    J Renin Angiotensin Aldosterone Syst 14:161-6. 2013
  10. doi request reprint Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients
    Stine E Nielsen
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Diabetes Res Clin Pract 97:71-6. 2012

Detail Information

Publications84

  1. ncbi request reprint Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus
    P Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabet Med 15:900-19. 1998
    ..Although the prognosis has improved remarkably, the primary goal should be prevention of diabetic nephropathy, as it is unlikely that the increased risks associated with this complication can be eliminated...
  2. ncbi request reprint Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus
    P Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabet Med 18:199-205. 2001
    ..To evaluate prolonged QTc interval and QT dispersion as predictors of all-cause and cardiovascular mortality after adjustment for well-established risk factors in Type 1 diabetic patients...
  3. ncbi request reprint Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study
    Peter Rossing
    Steno Diabetes Center, Gentofte, Denmark Novo Nordisk, Biostatistics, Bagsvaerd, Denmark
    Diabetes Care 25:859-64. 2002
    ..To evaluate prospectively putative risk factors for development of microalbuminuria and macroalbuminuria in type 1 diabetes...
  4. ncbi request reprint Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Steen Andersen
    Steno Diabetes Center, Copenhagen, Denmark
    Diabetes Care 26:1501-6. 2003
    ..Therefore, we investigated the long-term effect of the angiotensin II subtype-1 (AT1) receptor antagonist losartan (100 mg o.d.) on kidney function in II and DD type 1 diabetic patients with diabetic nephropathy...
  5. doi request reprint Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate
    Henrik Reinhard
    Steno Diabetes Centre, Gentofte, Denmark
    Nephrol Dial Transplant 26:3242-9. 2011
    ....
  6. pmc 24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study
    Simone Theilade
    Steno Diabetes Center, Niels Steensensvej 1, 2820 Gentofte, Denmark
    Cardiovasc Diabetol 12:122. 2013
    ..We evaluate the relationship between 24 h central blood pressure and diabetes-related complications in patients with type 1 diabetes...
  7. pmc NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients
    Henrik Reinhard
    Steno Diabetes Center, Niels Steensenvej 1, DK 2820 Gentofte, Denmark
    Cardiovasc Diabetol 11:19. 2012
    ....
  8. ncbi request reprint Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    Scand J Clin Lab Invest 68:731-8. 2008
    ....
  9. doi request reprint Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease
    Stine E Nielsen
    Steno Diabetes Center, Gentofte, Denmark
    J Renin Angiotensin Aldosterone Syst 14:161-6. 2013
    ..We investigated the effect of spironolactone added to standard RAAS blockade on these biomarkers in an analysis of four original studies...
  10. doi request reprint Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients
    Stine E Nielsen
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Diabetes Res Clin Pract 97:71-6. 2012
    ..Our aim was to investigate u-NGAL, u-KIM1 and p-FGF23 and prediction of decline in kidney function in type 2 diabetic patients with proteinuria...
  11. ncbi request reprint Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy
    Steen Andersen
    Steno Diabetes Center, Niels Steensensvej 2, DK 2820 Gentofte, Denmark
    Nephrol Dial Transplant 18:293-7. 2003
    ..We evaluated the time course of the antihypertensive and antialbuminuric effect after initiation of AT1 receptor blockade by losartan in diabetic nephropathy...
  12. ncbi request reprint Progression of nephropathy in type 2 diabetic patients
    Kasper Rossing
    Department of Physiology, Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 66:1596-605. 2004
    ....
  13. doi request reprint Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    J Renin Angiotensin Aldosterone Syst 13:250-3. 2012
    ..This post-hoc analysis assessed the influence of baseline glycaemic control on the reduction of albuminuria with aliskiren or placebo added to losartan in the Aliskiren in the EValuation of PrOteinuria In Diabetes (AVOID) study...
  14. pmc Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy
    Maria Lajer
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 33:1567-72. 2010
    ..The aim of this study was to investigate GDF-15 levels in relation to all-cause mortality, cardiovascular mortality and morbidity, decline in glomerular filtration rate (GFR), and progression toward end-stage renal disease (ESRD)...
  15. pmc Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 32:1873-9. 2009
    ..We investigated whether the antiproteinuric effect of the direct renin inhibitor aliskiren is comparable to that of irbesartan and the effect of the combination...
  16. ncbi request reprint Optimal dose of losartan for renoprotection in diabetic nephropathy
    Steen Andersen
    Steno Diabetes Center, Copenhagen, Denmark
    Nephrol Dial Transplant 17:1413-8. 2002
    ..The aim of our study was to evaluate the optimal dose of losartan for renoprotection and blood pressure reduction in diabetic nephropathy...
  17. pmc NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis
    Henrik Reinhard
    Steno Diabetes Center, Gentofte, Denmark
    Cardiovasc Diabetol 10:71. 2011
    ....
  18. doi request reprint Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function
    Maria Lajer
    Steno Diabetes Center, Gentofte, Denmark
    Platelets 21:525-32. 2010
    ..85) nor rate of decline in GFR (p = 0.69). Plasma sCD40L is elevated in T1DM nephropathy but is not a predictor of all-cause mortality, cardiovascular mortality and morbidity or deterioration of kidney function..
  19. pmc Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy
    Frederik Persson
    Steno Diabetes Center, Niels Steensensvej 1, DK 2820 Gentofte, Denmark
    Clin J Am Soc Nephrol 6:1025-31. 2011
    ..Our post hoc analysis assessed the baseline BP influence on the antiproteinuric effect in the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) study...
  20. doi request reprint Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate
    Anne Sofie Astrup
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 31:1170-6. 2008
    ..We evaluated the association of biomarkers of endothelial dysfunction and inflammation with all-cause mortality and cardiovascular mortality and morbidity and decline in glomerular filtration rate (GFR) in type 1 diabetic patients...
  21. ncbi request reprint Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy
    Maria Lajer
    Steno Diabetes Center, Niels Steensens Vej 1, 2820 Gentofte, Denmark
    Diabetes Care 31:747-52. 2008
    ....
  22. pmc Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate
    Christel Joergensen
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 35:168-72. 2012
    ..Coronary artery disease (CAD) is the major cause of morbidity and mortality in type 2 diabetic patients. Severe vitamin D deficiency has been shown to predict cardiovascular mortality in type 2 diabetic patients...
  23. ncbi request reprint [Risk factors for the development of microalbuminuria in type 1 diabetes: an incidence cohort study--a secondary publication]
    Peter Hovind
    Steno Diabetes Center, Gentofte
    Ugeskr Laeger 167:57-60. 2005
  24. ncbi request reprint Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points
    Hans Henrik Parving
    Steno Diabetes Center, Copenhagen, Denmark
    Semin Nephrol 24:147-57. 2004
    ..The studies mentioned here suggest that ARB represents a beneficial treatment of hypertension and proteinuria in incipient and overt diabetic nephropathy...
  25. pmc Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients
    Henrik Reinhard
    Steno Diabetes Center, Gentofte, Denmark
    Cardiovasc Diabetol 11:119. 2012
    ..We assessed the association between P-NT-proBNP and WMH or brain atrophy measured with magnetic resonance imaging (MRI) in type 2 diabetic patients, and age-matched controls...
  26. doi request reprint Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    J Renin Angiotensin Aldosterone Syst 13:118-21. 2012
    ..This study assessed the effects of direct renin inhibition with aliskiren in combination with losartan and optimal antihypertensive therapy on urinary aldosterone, plasma renin activity (PRA) and plasma renin concentration (PRC)...
  27. ncbi request reprint Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy
    Anders Jorsal
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 74:649-54. 2008
    ..These studies show that high serum adiponectin levels predict mortality and progression to end stage renal disease in type I diabetic patients...
  28. pmc Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study
    Peter Hovind
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes 58:1668-71. 2009
    ..Whether uric acid has a causal role in the development of diabetic nephropathy is not known. The objective of the present study is to evaluate uric acid as a predictor of persistent micro- and macroalbuminuria...
  29. ncbi request reprint Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes
    Anders Jorsal
    Steno Diabetes Center, Gentofte, Denmark Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark Institute of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark Electronic address
    J Diabetes Complications 27:604-8. 2013
    ..Inspired by this, we studied the levels of u-adiponectin in type 1 diabetic patients with different levels of urinary albumin excretion (UAE)...
  30. doi request reprint Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    J Hypertens 31:1646-52. 2013
    ..Our aim was to determine whether urinary angiotensinogen and renin are circulating RAAS-independent markers during RAAS blockade...
  31. pmc Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients
    Stine Elkjaer Nielsen
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 33:1320-4. 2010
    ..Our aim was to evaluate u-LFABP as a predictor of progression to micro- and macroalbuminuria in type 1 diabetes...
  32. pmc Tubular and glomerular injury in diabetes and the impact of ACE inhibition
    Stine E Nielsen
    Steno Diabetes Center, Copenhagen, Denmark
    Diabetes Care 32:1684-8. 2009
    ..Subsequently, we evaluated the effect of ACE inhibition on U-LFABP in patients with diabetic nephropathy...
  33. pmc Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study
    Søren Søgaard Lund
    Steno Diabetes Center, Gentofte, Denmark
    PLoS ONE 3:e3363. 2008
    ..We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and persistent poor glycaemic control...
  34. pmc Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 33:2304-9. 2010
    ..This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD])...
  35. pmc Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study
    Peter Hovind
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    BMJ 328:1105. 2004
    ..To evaluate baseline predictors for the development of persistent microalbuminuria and macroalbuminuria prospectively in patients with type 1 diabetes...
  36. ncbi request reprint Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy
    Steen Andersen
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 67:2325-9. 2005
    ..The present study aimed to investigate the short- and long term effects of angiotensin II receptor blockade by Losartan on urinary CTGF levels in hypertensive type 1 diabetic patients with diabetic nephropathy...
  37. ncbi request reprint Smoking and progression of diabetic nephropathy in type 1 diabetes
    Peter Hovind
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 26:911-6. 2003
    ..We assessed the impact of smoking on progression of diabetic nephropathy in type 1 diabetic patients enrolled in a prospective observational cohort study started in 1983...
  38. ncbi request reprint Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy
    Peter Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 29:1024-30. 2006
    ....
  39. doi request reprint Discrepancy between tonometric ambulatory and cuff-based office blood pressure measurements in patients with type 1 diabetes
    Simone Theilade
    Steno Diabetes Center, Gentofte, Denmark
    J Clin Hypertens (Greenwich) 14:686-93. 2012
    ..ABP and OBP disagree in diagnosing HTN in 31% to 37% of patients. Furthermore, 55% to 66% of patients do not reach target BP of <130/80 mm Hg despite regular follow-up...
  40. ncbi request reprint Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study
    Peter Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:1446-50. 2005
  41. ncbi request reprint Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy
    Frederik Persson
    Steno Diabetes Center, Niels Steensenvej 2, DK 2820 Gentofte, Denmark
    Diabetes 55:3550-5. 2006
    ..04). There was no treatment effect on the other biomarkers. Irbesartan (300 mg once daily) reduces low-grade inflammation in this high-risk population, and this may reduce the risk of micro- and macrovascular disease...
  42. ncbi request reprint Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study
    Anne Sofie Astrup
    Steno Diabetes Center, Gentofte, Denmark
    J Hypertens 25:2479-85. 2007
    ..To evaluate the prognostic significance of cardiovascular risk factors including 24-h ambulatory blood pressure level and rhythm for all-cause mortality in type 2 diabetic patients...
  43. ncbi request reprint Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy
    Peter Hovind
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 66:1180-6. 2004
    ....
  44. ncbi request reprint Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes
    Peter Hovind
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 26:1258-64. 2003
    ..To assess recent trends in the cumulative incidence of diabetic microangiopathy in type 1 diabetes, we analyzed data from long-term prospective observational studies lasting >/=20 years...
  45. pmc Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes
    Simone Theilade
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 36:715-21. 2013
    ..In patients with type 1 diabetes, we investigated the association between arterial stiffness and diabetes complications...
  46. doi request reprint The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP
    Stine E Nielsen
    Steno Diabetes Center, Gentofte, Denmark
    Scand J Clin Lab Invest 72:137-42. 2012
    ..We aimed to investigate the effect of irbesartan on the tubular markers: urinary (u) neutrophil gelatinase associated protein (NGAL), Kidney injury molecule 1 (KIM1) and liver-fatty acid-binding protein (LFABP)...
  47. doi request reprint Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study
    Stine Elkjaer Nielsen
    Steno Diabetes Center, Gentofte, Denmark
    Nephron Clin Pract 118:c130-5. 2011
    ..We evaluated urinary (u)-NGAL as a predictor of progression in diabetic nephropathy in type 1 diabetic (T1D) patients...
  48. pmc Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
    Sten Andersen
    Steno Diabetes Centre, Gentofte, Denmark
    BMC Nephrol 11:29. 2010
    ..The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome...
  49. doi request reprint Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy
    Henrik Reinhard
    Steno Diabetes Center, Gentofte, Denmark hnri steno dk
    Nephron Clin Pract 118:c309-14. 2011
    ..Our aim was to evaluate EPC numbers in asymptomatic CVD type 1 diabetic patients with or without DN and to study the effect of CVD and medication on EPC numbers...
  50. doi request reprint Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy
    Stine E Nielsen
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 79:1113-8. 2011
    ..Thus, urine biomarker measurements in patients with type 1 diabetic nephropathy did not provide additional prognostic information to that of known progression promoters...
  51. pmc Urinary proteomics in diabetes and CKD
    Kasper Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    J Am Soc Nephrol 19:1283-90. 2008
    ..In conclusion, this study shows that analysis of the urinary proteome may allow early detection of diabetic nephropathy and may provide prognostic information...
  52. doi request reprint Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis
    Henning G Hansen
    Hagedorn Research Institute, Novo Nordisk A S, Gentofte, Denmark
    Proteomics Clin Appl 4:697-705. 2010
    ..The aim of this study was to discover candidate biomarkers for DN in the plasma peptidome in an in-house cross-sectional cohort (n=122) of type 1 diabetic patients diagnosed with normo-, micro-, and macroalbuminuria...
  53. pmc Direct renin inhibition in chronic kidney disease
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    Br J Clin Pharmacol 76:580-6. 2013
    ..In this review we provide the current evidence for renin inhibition in chronic kidney disease by reporting the studies published so far as well as a perspective on the future possibilities...
  54. doi request reprint Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes: comparison of the BPro and SphygmoCor devices
    Simone Theilade
    Steno Diabetes Center, Gentofte, Denmark
    Blood Press Monit 18:156-60. 2013
    ..We investigate whether tonometric measurements are feasible in patients with diabetes and whether the degree of albuminuria or increased arterial stiffness affects measurements...
  55. ncbi request reprint Beneficial impact of spironolactone in diabetic nephropathy
    Katrine Jordan Schjoedt
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:2829-36. 2005
    ..We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on albuminuria and blood pressure in diabetic nephropathy...
  56. ncbi request reprint Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy
    Anne Sofie Astrup
    Steno Diabetes Center, Niels Steensensvej 2, 2820 Gentofte, Denmark
    Diabetes Care 29:334-9. 2006
    ..Because CAN is common in patients with diabetic nephropathy, we evaluated the predictive value of CAN in type 1 diabetic patients with and without diabetic nephropathy...
  57. doi request reprint Ambulatory tonometric blood pressure measurements in patients with diabetes
    Simone Theilade
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Technol Ther 14:453-6. 2012
    ..In this study we investigate if arterial tonometry is applicable and reliable in patients with diabetes...
  58. pmc Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria
    Henrik Reinhard
    Steno Diabetes Center, Gentofte, Denmark
    Cardiovasc Diabetol 10:70. 2011
    ..We investigated the correlation between P-OPG and coronary artery disease (CAD) in asymptomatic type 2 diabetic patients with microalbuminuria...
  59. ncbi request reprint Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history
    Peter Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    Curr Diab Rep 6:479-83. 2006
    ....
  60. pmc Vitamin D levels, microvascular complications, and mortality in type 1 diabetes
    Christel Joergensen
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 34:1081-5. 2011
    ..To evaluate vitamin D as a predictor of all-cause mortality, progression from normoalbuminuria to micro- or macroalbuminuria, and the development of background or proliferative retinopathy in patients with type 1 diabetes...
  61. ncbi request reprint Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors
    Gudbjörg Andrésdottir
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 37:1660-7. 2014
    ....
  62. ncbi request reprint [Renal disease by type 2 diabetes]
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    Ugeskr Laeger 174:2150-4. 2012
    ..Although progress has been made over the last few decades, there is still an unmet need for improved screening, prevention and treatment since both cardiac and renal morbidity and mortality remains severe in this group of patients...
  63. doi request reprint High YKL-40 levels predict mortality in patients with type 2 diabetes
    Frederik Persson
    Steno Diabetes Center, Niels Steensenvej 2, Gentofte, Denmark
    Diabetes Res Clin Pract 96:84-9. 2012
    ..We determined levels of the inflammatory marker YKL-40 in a population of patients with type 2 diabetes (T2D) and investigated the association with mortality...
  64. pmc Vitamin D levels and mortality in type 2 diabetes
    Christel Joergensen
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 33:2238-43. 2010
    ..To evaluate vitamin D as a predictor of all-cause and cardiovascular mortality and risk of progression to micro- or macroalbuminuria in type 2 diabetic patients...
  65. ncbi request reprint Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study
    Anne Sofie Astrup
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:1250-7. 2005
    ..Furthermore, end-stage renal disease (ESRD) was the main cause of death. We prospectively assessed the impact of reno- and cardiovascular protective treatment on prognosis in type 1 diabetic patients with diabetic nephropathy...
  66. pmc Osteoprotegerin and mortality in type 2 diabetic patients
    Henrik Reinhard
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 33:2561-6. 2010
    ..We aimed to investigate the prognostic value of OPG in relation to all-cause and cardiovascular mortality in a cohort of type 2 diabetic patients...
  67. ncbi request reprint Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Steen Andersen
    Steno Diabetes Center, Niels Steensensvej 2, 2820 Gentofte, Copenhagen, Denmark
    Kidney Int 62:192-8. 2002
    ..In an attempt to overcome this interaction, we evaluated the short-term renoprotective effect in diabetic nephropathy of the angiotensin II receptor antagonist losartan in patients homozygous for the insertion or the deletion allele...
  68. ncbi request reprint [Hypertension in patients with diabetes]
    Per Løgstrup Poulsen
    Medicinsk Afdeling M, Arhus Sygehus, DK 8000 Arhus
    Ugeskr Laeger 171:2031-4. 2009
    ..Long-term data are awaited regarding the optimal strategy for combination therapy. Patients on intensive antihypertensive treatment should be monitored regularly...
  69. pmc YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria
    Camilla Noelle Rathcke
    Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
    Diabetes Care 32:323-8. 2009
    ..In the present study, YKL-40 levels were examined in patients with type 1 diabetes with increasing levels of albuminuria, known to be associated with an increased risk of cardiovascular disease...
  70. pmc ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy
    Hans Henrik Parving
    Department of Medical Endocrinology, Department 2132, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen Ø, Denmark
    J Am Soc Nephrol 19:771-9. 2008
    ..In conclusion, proteinuric type 2 diabetic patients with the D allele of the ACE gene have an unfavorable renal prognosis, which can be mitigated and even improved by losartan...
  71. ncbi request reprint Need for better diabetes treatment for improved renal outcome
    Peter Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int Suppl . 2011
    ..However, studies with renal end points using these agents are lacking...
  72. doi request reprint The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Proteomics Clin Appl 2:997-1007. 2008
    ..Therefore, urinary proteome analysis might enable noninvasive assessment of this process at an early stage via determination of specific collagen fragments. This may open an avenue towards targeted therapeutic intervention...
  73. pmc Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy
    Anne Julie Overgaard
    Department of Genome Biology, Hagedorn Research Institute, Gentofte, Denmark
    Proteome Sci 8:4. 2010
    ..CONCLUSION: These results demonstrate the capacity of proteomic analysis of plasma, by confirming the presence of known biomarkers as well as revealing new biomarkers for diabetic nephropathy in plasma in type 1 diabetic patients...
  74. ncbi request reprint Renoprotective effects of renin-angiotensin-system inhibitors
    Hans Henrik Parving
    Lancet 367:898-9; author reply 900-2. 2006
  75. doi request reprint Elevated levels of high-molecular-weight adiponectin in type 1 diabetes
    Henrik Leth
    The Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Nørrebrogade 44, DK 8000 Aarhus C, Denmark
    J Clin Endocrinol Metab 93:3186-91. 2008
    ..The effects of the medium-molecular-weight (MMW) subform and the low-molecular-weight (LMW) subform are still unresolved...
  76. doi request reprint Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy
    Tri Q Nguyen
    Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
    Diabetes Care 31:1177-82. 2008
    ..We evaluated the predictive value of baseline plasma connective tissue growth factor (CTGF) in a prospective study of patients with type 1 diabetes...
  77. doi request reprint Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
    Nish Chaturvedi
    International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College Healthcare NHS Trust, London, UK
    Lancet 372:1394-402. 2008
    ..We therefore designed the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme to assess whether candesartan could reduce the incidence and progression of retinopathy in type 1 diabetes...
  78. doi request reprint Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
    Anne Katrin Sjølie
    Department of Ophthalmology, Odense University Hospital, Odense, Denmark
    Lancet 372:1385-93. 2008
    ..Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes...
  79. ncbi request reprint [ACE inhibitors and AT-II antagonists--do they protect against renal disease?]
    Peter Rossing
    Ugeskr Laeger 168:1564; author reply1564-5. 2006
  80. ncbi request reprint Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy
    Peter Karl Jacobsen
    Nephrol Dial Transplant 21:2030-1. 2006
  81. ncbi request reprint Telmisartan vs. enalapril in type 2 diabetes
    Hans Henrik Parving
    N Engl J Med 352:835-6; author reply 835-6. 2005
  82. ncbi request reprint Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes
    Peter Rossing
    Diabetes Care 29:747-8; author reply 748-9. 2006
  83. ncbi request reprint Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
    Peter Rossing
    Nephrol Dial Transplant 21:2354-7; discussion 2357-8. 2006
  84. ncbi request reprint Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy
    Sofia B Ahmed
    Department of Medicine, Brigham and Women s Hospital, PBB 3, 75 Francis St, Boston, MA 02115, USA
    Diabetes Care 28:1988-94. 2005
    ..RAS activation occurs in healthy women using oral contraceptives (OCs), but the effects of OC use on the diabetic kidney are unclear...